{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:47:49Z","timestamp":1761976069101},"reference-count":65,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"DOI":"10.7759\/cureus.49332","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T11:29:30Z","timestamp":1700825370000},"source":"Crossref","is-referenced-by-count":1,"title":["Adverse Drug Effect Profiles of Gp2b\/3a Inhibitors: A Comparative Review of the Last Two Decades"],"prefix":"10.7759","author":[{"given":"Naziha","family":"Hasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Jauregui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahrukh","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venugopala K","family":"Pushparajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan J","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durga Manaswini","family":"Attaluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diny","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Jaisinghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Chuecos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Acute ST-Elevation Myocardial Infarction","author":"Akbar H","year":"2023","unstructured":"Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Elevation Myocardial Infarction. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref2","article-title":"Mechanisms of Plaque Rupture. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists","author":"Loftus I","year":"2011","unstructured":"Loftus I, Fitridge R, Thompson M. Mechanisms of Plaque Rupture. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists.  University of Adelaide Press, South Australia; 2011."},{"key":"ref3","article-title":"Acute Coronary Syndrome","author":"Singh A","year":"2023","unstructured":"Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction","volume":"138","author":"Thygesen K","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction. Circulation. 2018, 138:e618-51. 10.1161\/CIR.0000000000000617","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2459\/01.JCM.0000362039.48638.92","article-title":"High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome?","volume":"10","author":"Manari A","year":"2009","unstructured":"Manari A, Albiero R, De Servi S. High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome?. J Cardiovasc Med (Hagerstown). 2009, 10:S13-6. 10.2459\/01.JCM.0000362039.48638.92","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1134","article-title":"Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance","volume":"340","author":"Crowe E","year":"2010","unstructured":"Crowe E, Lovibond K, Gray H, Henderson R, Krause T, Camm J. Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance. BMJ. 2010, 340:c1134. 10.1136\/bmj.c1134","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review","volume":"327","author":"Bhatt DL","year":"2022","unstructured":"Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022, 327:662-75. 10.1001\/jama.2022.0358","journal-title":"JAMA"},{"key":"ref8","article-title":"Anterior Myocardial Infarction","author":"Bansal K","year":"2023","unstructured":"Bansal K, Gore M, Nalabothu P. Anterior Myocardial Infarction. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.001","article-title":"2007 focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"51","author":"Antman EM","year":"2008","unstructured":"Antman EM, Hand M, Armstrong PW, et al.. 2007 focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2008, 51:210-47. 10.1016\/j.jacc.2007.10.001","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742cf6","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara PT","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al.. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 127:e362-425. 10.1161\/CIR.0b013e3182742cf6","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000134","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam EA","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al.. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 130:e344-426. 10.1161\/CIR.0000000000000134","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-11-1133","article-title":"Nitroglycerin use in myocardial infarction patients","volume":"76","author":"Ferreira JC","year":"2012","unstructured":"Ferreira JC, Mochly-Rosen D. Nitroglycerin use in myocardial infarction patients. Circ J. 2012, 76:15-21. 10.1253\/circj.cj-11-1133","journal-title":"Circ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019872386","article-title":"Use of glycoprotein IIb\/IIIa inhibitors in the modern era of acute coronary syndrome management: a survey of cardiovascular clinical pharmacists","volume":"34","author":"Beavers CJ","year":"2021","unstructured":"Beavers CJ, Jennings DL. Use of glycoprotein IIb\/IIIa inhibitors in the modern era of acute coronary syndrome management: a survey of cardiovascular clinical pharmacists. J Pharm Pract. 2021, 34:372-7. 10.1177\/0897190019872386","journal-title":"J Pharm Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2015.10.009","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without Persistent ST-segment elevation","volume":"68","author":"Roffi M","year":"2015","unstructured":"Roffi M, Patrono C, Collet JP, et al.. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without Persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2015, 68:1125. 10.1016\/j.rec.2015.10.009","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4065\/84.10.917","article-title":"Acute coronary syndromes: diagnosis and management, part I","volume":"84","author":"Kumar A","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009, 84:917-938. 10.4065\/84.10.917","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2015.02.140189","article-title":"Diagnosis and management of acute coronary syndrome: an evidence-based update","volume":"28","author":"Smith JN","year":"2015","unstructured":"Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015, 28:283-93. 10.3122\/jabfm.2015.02.140189","journal-title":"J Am Board Fam Med"},{"key":"ref17","article-title":"Glycoprotein IIb\/IIIa Inhibitors","author":"Tummala R","year":"2023","unstructured":"Tummala R, Rai MP. Glycoprotein IIb\/IIIa Inhibitors. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref18","unstructured":"U.S. Food and Drug Administration. Integrilin (eptifibatide) injection, for intravenous use. (2021). Accessed: July 30, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020718s039lbl.pdf."},{"key":"ref19","unstructured":"U.S. Food and Drug Administration. Aggrastat (tirofiban hydrochloride) injection, for intravenous use. (2019). Accessed: July 30, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1998\/20912lbl.pdf."},{"key":"ref20","article-title":"Abciximab","author":"Stoffer K","year":"2023","unstructured":"Stoffer K, Bistas KG, Reddy V, Shah S. Abciximab. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref21","article-title":"The clinical use of the GPIIb\/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the \"non-ST elevation\" type [Italian]","volume":"1","author":"Galli M","year":"2000","unstructured":"Galli M, Maggioni AP, Vassanelli C, Tavazzi L. The clinical use of the GPIIb\/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the \"non-ST elevation\" type [Italian]. Ital Heart J Suppl. 2000, 1:202-11.","journal-title":"Ital Heart J Suppl"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp118","article-title":"Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials","volume":"30","author":"De Luca G","year":"2009","unstructured":"De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009, 30:2705-13. 10.1093\/eurheartj\/ehp118","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4021\/cr251w","article-title":"Is there still a role for glycoprotein IIb\/IIIa antagonists in acute coronary syndromes?","volume":"4","author":"Iannetta L","year":"2013","unstructured":"Iannetta L, Puddu PE, Cuturello D, Saladini A, Pellicano M, Schiariti M. Is there still a role for glycoprotein IIb\/IIIa antagonists in acute coronary syndromes?. Cardiol Res. 2013, 4:1-7. 10.4021\/cr251w","journal-title":"Cardiol Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000029744.01096.1f","article-title":"Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial","volume":"106","author":"Batchelor WB","year":"2002","unstructured":"Batchelor WB, Tolleson TR, Huang Y, et al.. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation. 2002, 106:1470-6. 10.1161\/01.cir.0000029744.01096.1f","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/hj.1999.v138.a100460","article-title":"Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective","volume":"138","author":"Dyke CM","year":"1999","unstructured":"Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective. Am Heart J. 1999, 138:307-16. 10.1053\/hj.1999.v138.a100460","journal-title":"Am Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.2_suppl.53S","article-title":"Immune thrombocytopenia caused by glycoprotein IIb\/IIIa inhibitors","volume":"127","author":"Aster RH","year":"2005","unstructured":"Aster RH. Immune thrombocytopenia caused by glycoprotein IIb\/IIIa inhibitors. Chest. 2005, 127:53S-9S. 10.1378\/chest.127.2_suppl.53S","journal-title":"Chest"},{"key":"ref27","article-title":"Eptifibatide","author":"Bansal AB","year":"2023","unstructured":"Bansal AB, Sattar Y, Jamil RT. Eptifibatide. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1328881","article-title":"Drugs that affect platelet function","volume":"38","author":"Scharf RE","year":"2012","unstructured":"Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost. 2012, 38:865-83. 10.1055\/s-0032-1328881","journal-title":"Semin Thromb Hemost"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10392","article-title":"Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension","volume":"58","author":"Rezkalla SH","year":"2003","unstructured":"Rezkalla SH, Hayes JJ, Curtis BR, Aster RH. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv. 2003, 58:76-9. 10.1002\/ccd.10392","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2006.07.005","article-title":"An audit of the use and complications of glycoprotein IIb\/IIIa inhibitors in percutaneous coronary intervention against national UK standards","volume":"7","author":"Sheikh A","year":"2006","unstructured":"Sheikh A, Baig K. An audit of the use and complications of glycoprotein IIb\/IIIa inhibitors in percutaneous coronary intervention against national UK standards. Cardiovasc Revasc Med. 2006, 7:237-9. 10.1016\/j.carrev.2006.07.005","journal-title":"Cardiovasc Revasc Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-13-4-248","article-title":"Eptifibatide-induced profound thrombocytopenia after percutaneous intervention for acute coronary syndrome: a challenging clinical scenario","volume":"13","author":"Bhatia N","year":"2017","unstructured":"Bhatia N, Sawyer RD, Ikram S. Eptifibatide-induced profound thrombocytopenia after percutaneous intervention for acute coronary syndrome: a challenging clinical scenario. Methodist Debakey Cardiovasc J. 2017, 13:248-52. 10.14797\/mdcj-13-4-248","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8817067","article-title":"Acute profound thrombocytopenia induced by eptifibatide causing diffuse alveolar hemorrhage","volume":"2021","author":"Byrd G","year":"2021","unstructured":"Byrd G, Custovic S, Byrd D, Ingrassia Miano D, Bathla J, Attallah A. Acute profound thrombocytopenia induced by eptifibatide causing diffuse alveolar hemorrhage. Case Rep Crit Care. 2021, 2021:8817067. 10.1155\/2021\/8817067","journal-title":"Case Rep Crit Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25731","article-title":"Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation","volume":"85","author":"Choi AW","year":"2015","unstructured":"Choi AW, Blair JE, Flaherty JD. Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation. Catheter Cardiovasc Interv. 2015, 85:828-31. 10.1002\/ccd.25731","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-8785-1","article-title":"Eptifibatide-induced thrombocytopenia and thrombosis","volume":"22","author":"Epelman S","year":"2006","unstructured":"Epelman S, Nair D, Downey R, Militello M, Askari AT. Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis. 2006, 22:151-4. 10.1007\/s11239-006-8785-1","journal-title":"J Thromb Thrombolysis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29549","article-title":"Eptifibatide-induced severe thrombocytopenia after ST-elevation myocardial infarction (STEMI): a case report","volume":"14","author":"Gheith Z","year":"2022","unstructured":"Gheith Z, Kilani A, Nguyen T. Eptifibatide-induced severe thrombocytopenia after ST-elevation myocardial infarction (STEMI): a case report. Cureus. 2022, 14:e29549. 10.7759\/cureus.29549","journal-title":"Cureus"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18217","article-title":"Tirofiban: a rare cause of thrombocytopenia in a patient undergoing percutaneous coronary intervention","volume":"13","author":"Gulati A","year":"2021","unstructured":"Gulati A, Tiwari A, Shetty V, Nwosu I, Khurana S. Tirofiban: a rare cause of thrombocytopenia in a patient undergoing percutaneous coronary intervention. Cureus. 2021, 13:e18217. 10.7759\/cureus.18217","journal-title":"Cureus"},{"key":"ref37","article-title":"Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty","volume":"39","author":"Guo J","year":"2012","unstructured":"Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012, 39:99-103.","journal-title":"Tex Heart Inst J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2008.23.3.156","article-title":"Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab","volume":"23","author":"Moon SJ","year":"2008","unstructured":"Moon SJ, Yoon HJ, Her SH, Lee JM, An HJ, Lee YJ, Jin SW. Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab. Korean J Intern Med. 2008, 23:156-60. 10.3904\/kjim.2008.23.3.156","journal-title":"Korean J Intern Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2016.06.003","article-title":"Delayed severe abciximab-induced thrombocytopenia: a case report","volume":"45","author":"Pi\u0105tek \u0141","year":"2016","unstructured":"Pi\u0105tek \u0141, Janion-Sadowska A, Kurzawski J, Grabowska U, Janion M. Delayed severe abciximab-induced thrombocytopenia: a case report. Heart Lung. 2016, 45:464-5. 10.1016\/j.hrtlng.2016.06.003","journal-title":"Heart Lung"},{"key":"ref40","article-title":"Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia","volume":"38","author":"Yang EH","year":"2011","unstructured":"Yang EH, Perez E, Zhiroff KA, Burstein S. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia. Tex Heart Inst J. 2011, 38:174-8.","journal-title":"Tex Heart Inst J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221182","article-title":"Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention","volume":"2017","author":"Golden T","year":"2017","unstructured":"Golden T, Ghazala S, Wadeea R, Junna S. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep. 2017, 2017:10.1136\/bcr-2017-221182","journal-title":"BMJ Case Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2010.02.002","article-title":"A fatal complication of tirofiban in an octogenarian: diffuse alveolar hemorrhage","volume":"2","author":"\u0130lhan E","year":"2010","unstructured":"\u0130lhan E, G\u00fcven\u00e7 TS, G\u00fczelbur\u00e7 \u00d6, et al.. A fatal complication of tirofiban in an octogenarian: diffuse alveolar hemorrhage. J Cardiol Cases. 2010, 2:e48-51. 10.1016\/j.jccase.2010.02.002","journal-title":"J Cardiol Cases"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-007-0166-x","article-title":"Eptifibatide-induced thrombocytopenia","volume":"25","author":"Refaat M","year":"2008","unstructured":"Refaat M, Smith AJ, Edmundowicz D. Eptifibatide-induced thrombocytopenia. J Thromb Thrombolysis. 2008, 25:204-6. 10.1007\/s11239-007-0166-x","journal-title":"J Thromb Thrombolysis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.02.006","article-title":"Delayed thrombocytopenia following administration of abciximab: pharmacovigilance survey and literature review","volume":"76","author":"Vincent L","year":"2021","unstructured":"Vincent L, Bourneau-Martin D, Maurier A, et al.. Delayed thrombocytopenia following administration of abciximab: pharmacovigilance survey and literature review. Therapie. 2021, 76:687-93. 10.1016\/j.therap.2021.02.006","journal-title":"Therapie"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2012.11928873","article-title":"Acute profound thrombocytopenia secondary to local abciximab infusion","volume":"25","author":"Peters MN","year":"2012","unstructured":"Peters MN, Press CD, Moscona JC, et al.. Acute profound thrombocytopenia secondary to local abciximab infusion. Proc (Bayl Univ Med Cent). 2012, 25:346-8. 10.1080\/08998280.2012.11928873","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2165\/11595010-000000000-00000","article-title":"Optimal use of platelet glycoprotein IIb\/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions","volume":"71","author":"Starnes HB","year":"2011","unstructured":"Starnes HB, Patel AA, Stouffer GA. Optimal use of platelet glycoprotein IIb\/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. Drugs. 2011, 71:2009-30. 10.2165\/11595010-000000000-00000","journal-title":"Drugs"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.4065\/77.12.1340","article-title":"Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy","volume":"77","author":"Choi RK","year":"2002","unstructured":"Choi RK, Lee NH, Lim DS, Hong Sk, Hwang HK. Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy. Mayo Clin Proc. 2002, 77:1340-3. 10.4065\/77.12.1340","journal-title":"Mayo Clin Proc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1885-5857(06)60654-3","article-title":"Extreme thrombocytopenia following Abciximab therapy","volume":"57","author":"Manzanares RMA","year":"2004","unstructured":"Manzanares RMA, Amaya MD, Ram\u00edrez JAB, Palomino MAP, Garc\u00eda DMA, Castro JLC. Extreme thrombocytopenia following Abciximab therapy. Revista Espa\u00f1ola de Cardiolog\u00eda. 2004, 57:885-888. 10.1016\/S1885-5857(06)60654-3","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065446","article-title":"Eptifibatide, an older therapeutic peptide with new indications: from clinical pharmacology to everyday clinical practice","volume":"24","author":"Tonin G","year":"2023","unstructured":"Tonin G, Klen J. Eptifibatide, an older therapeutic peptide with new indications: from clinical pharmacology to everyday clinical practice. Int J Mol Sci. 2023, 24:10.3390\/ijms24065446","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303411","article-title":"Targeting integrin and integrin signaling in treating thrombosis","volume":"35","author":"Estevez B","year":"2015","unstructured":"Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015, 35:24-9. 10.1161\/ATVBAHA.114.303411","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang X","year":"2023","unstructured":"Pang X, He X, Qiu Z, et al.. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023, 8:1. 10.1038\/s41392-022-01259-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(99)70075-x","article-title":"Development of eptifibatide","volume":"138","author":"Scarborough RM","year":"1999","unstructured":"Scarborough RM. Development of eptifibatide. Am Heart J. 1999, 138:1093-1104. 10.1016\/s0002-8703(99)70075-x","journal-title":"Am Heart J"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips DR","year":"1997","unstructured":"Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997, 80:11-20. 10.1016\/s0002-9149(97)00572-9","journal-title":"Am J Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.8.1147","article-title":"The role of eptifibatide in patients undergoing percutaneous coronary intervention","volume":"8","author":"Zeymer U","year":"2007","unstructured":"Zeymer U. The role of eptifibatide in patients undergoing percutaneous coronary intervention. Expert Opin Pharmacother. 2007, 8:1147-54. 10.1517\/14656566.8.8.1147","journal-title":"Expert Opin Pharmacother"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321120-00005","article-title":"Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes","volume":"21","author":"Plosker GL","year":"2003","unstructured":"Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics. 2003, 21:885-912. 10.2165\/00019053-200321120-00005","journal-title":"Pharmacoeconomics"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211006645","article-title":"Complications and management of eptifibatide-induced thrombocytopenia","volume":"55","author":"Masood F","year":"2021","unstructured":"Masood F, Hashmi S, Chaus A, Hertsberg A, Ehrenpreis ED. Complications and management of eptifibatide-induced thrombocytopenia. Ann Pharmacother. 2021, 55:1467-73. 10.1177\/10600280211006645","journal-title":"Ann Pharmacother"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne C","year":"2020","unstructured":"Vayne C, Gu\u00e9ry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020, 9:10.3390\/jcm9072212","journal-title":"J Clin Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.07.132","article-title":"Eptifibatide overdose","volume":"131","author":"Parakh S","year":"2009","unstructured":"Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K. Eptifibatide overdose. Int J Cardiol. 2009, 131:430-2. 10.1016\/j.ijcard.2007.07.132","journal-title":"Int J Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03961-x","article-title":"Influence of integrins on thrombus formation: a road leading to the unravelling of DVT","volume":"476","author":"Ghosh N","year":"2021","unstructured":"Ghosh N, Garg I, Srivastava S, Kumar B. Influence of integrins on thrombus formation: a road leading to the unravelling of DVT. Mol Cell Biochem. 2021, 476:1489-504. 10.1007\/s11010-020-03961-x","journal-title":"Mol Cell Biochem"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"The RESTORE Investigators","year":"1997","unstructured":"The RESTORE Investigators. Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997, 96:1445-53. 10.1161\/01.cir.96.5.1445","journal-title":"Circulation"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.02.016","article-title":"A prospective, randomized evaluation of a novel Everolimus-Eluting Coronary Stent: the platinum (a prospective, randomized, multicenter trial to assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the treatment of up to two De novo coronary artery lesions) trial","volume":"57","author":"Stone GW","year":"2011","unstructured":"Stone GW, Teirstein PS, Meredith IT, et al.. A prospective, randomized evaluation of a novel Everolimus-Eluting Coronary Stent: the platinum (a prospective, randomized, multicenter trial to assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the treatment of up to two De novo coronary artery lesions) trial. J Am Coll Cardiol. 2011, 57:1700-8. 10.1016\/j.jacc.2011.02.016","journal-title":"J Am Coll Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial","volume":"372","author":"Van't Hof AW","year":"2008","unstructured":"Van't Hof AW, Ten Berg J, Heestermans T, et al.. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial. Lancet. 2008, 372:537-546. 10.1016\/s0140-6736(08)61235-0","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30287","article-title":"Prolonged use of tirofiban infusion without percutaneous coronary intervention to achieve optimal results in a COVID-19 positive patient with inferior ST segment elevated myocardial infarction (STEMI) secondary to thromboembolism: a case report","volume":"14","author":"Khan Z","year":"2022","unstructured":"Khan Z, Patel N. Prolonged use of tirofiban infusion without percutaneous coronary intervention to achieve optimal results in a COVID-19 positive patient with inferior ST segment elevated myocardial infarction (STEMI) secondary to thromboembolism: a case report. Cureus. 2022, 14:e30287. 10.7759\/cureus.30287","journal-title":"Cureus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.03.030","article-title":"Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb\/IIIa antagonist","volume":"44","author":"Barrett YC","year":"2007","unstructured":"Barrett YC, Ebling W, Pieniaszek H, Billheimer J, Seiffert D. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb\/IIIa antagonist. J Pharm Biomed Anal. 2007, 44:938-46. 10.1016\/j.jpba.2007.03.030","journal-title":"J Pharm Biomed Anal"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.09.026","article-title":"The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: a systematic review and meta-analysis","volume":"147","author":"Oikonomou EK","year":"2016","unstructured":"Oikonomou EK, Repanas TI, Papanastasiou C, et al.. The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: a systematic review and meta-analysis. Thromb Res. 2016, 147:64-71. 10.1016\/j.thromres.2016.09.026","journal-title":"Thromb Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204221-adverse-drug-effect-profiles-of-gp2b3a-inhibitors-a-comparative-review-of-the-last-two-decades","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:16Z","timestamp":1707509416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204221-adverse-drug-effect-profiles-of-gp2b3a-inhibitors-a-comparative-review-of-the-last-two-decades"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":65,"URL":"https:\/\/doi.org\/10.7759\/cureus.49332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}